 Liquidia Technologies, Inc. LQDA, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT technology, will host a webcast and conference call on June 30, 2020 at 8:00 a.m. Eastern Time to provide an update on recent announcements regarding the proposed acquisition of RareGen, LLC, and the ongoing offering of common stock. Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT technology to transform the lives of patients. RareGen provides strategy, investment, and commercialization for rare disease pharmaceutical products. 